455 related articles for article (PubMed ID: 16477548)
21. Trichosporon beigelii, a new neonatal pathogen.
Yoss BS; Sautter RL; Brenker HJ
Am J Perinatol; 1997 Feb; 14(2):113-7. PubMed ID: 9259910
[TBL] [Abstract][Full Text] [Related]
22. Combined antifungal therapy in a murine infection by Candida glabrata.
Mariné M; Serena C; Pastor FJ; Guarro J
J Antimicrob Chemother; 2006 Dec; 58(6):1295-8. PubMed ID: 17012301
[TBL] [Abstract][Full Text] [Related]
23. Pathogenicity of Trichosporon asahii in a murine model of disseminated trichosporonosis.
Yang RY; Wang WL; Ao JH; Hao ZF; Zhang J; Wang CM
Chin Med J (Engl); 2008 Dec; 121(24):2557-60. PubMed ID: 19187595
[TBL] [Abstract][Full Text] [Related]
24. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.
Goodman D; Pamer E; Jakubowski A; Morris C; Sepkowitz K
Clin Infect Dis; 2002 Aug; 35(3):E35-6. PubMed ID: 12115115
[TBL] [Abstract][Full Text] [Related]
26. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
Li H; Lu Q; Wan Z; Zhang J
Int J Antimicrob Agents; 2010 Jun; 35(6):550-2. PubMed ID: 20202797
[TBL] [Abstract][Full Text] [Related]
27. Combined therapy in treatment of murine infection by Fusarium solani.
Ruíz-Cendoya M; Mariné M; Guarro J
J Antimicrob Chemother; 2008 Sep; 62(3):543-6. PubMed ID: 18495651
[TBL] [Abstract][Full Text] [Related]
28. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
[TBL] [Abstract][Full Text] [Related]
29. Micafungin: a new echinocandin antifungal.
Joseph JM; Jain R; Danziger LH
Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
[TBL] [Abstract][Full Text] [Related]
30. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
[TBL] [Abstract][Full Text] [Related]
31. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
[TBL] [Abstract][Full Text] [Related]
32. Micafungin (Mycamine) for fungal infections.
Med Lett Drugs Ther; 2005 Jun; 47(1211):51-2. PubMed ID: 15961968
[TBL] [Abstract][Full Text] [Related]
33. Combined therapies in a murine model of blastoschizomycosis.
Serena C; Rodríguez MM; Mariné M; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2007 Jul; 51(7):2608-10. PubMed ID: 17452487
[TBL] [Abstract][Full Text] [Related]
34. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
Santos RP; Sánchez PJ; Mejias A; Benjamin DK; Walsh TJ; Patel S; Jafri HS
Pediatr Infect Dis J; 2007 Apr; 26(4):364-6. PubMed ID: 17414408
[TBL] [Abstract][Full Text] [Related]
35. Liposomal amphotericin B: what is its role in 2008?
Lanternier F; Lortholary O
Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
[TBL] [Abstract][Full Text] [Related]
36. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.
Antachopoulos C; Papakonstantinou E; Dotis J; Bibashi E; Tamiolaki M; Koliouskas D; Roilides E
J Pediatr Hematol Oncol; 2005 May; 27(5):283-5. PubMed ID: 15891566
[TBL] [Abstract][Full Text] [Related]
37. The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.
Wiederhold NP; Lewis JS
Expert Opin Pharmacother; 2007 Jun; 8(8):1155-66. PubMed ID: 17516879
[TBL] [Abstract][Full Text] [Related]
38. Quantitative PCR assay used to monitor serum Trichosporon asahii DNA concentrations in disseminated trichosporonosis.
Tsuji Y; Tokimatsu I; Sugita T; Nozaki M; Kobayashi D; Imai K; Kogawa K; Nonoyama S
Pediatr Infect Dis J; 2008 Nov; 27(11):1035-7. PubMed ID: 18845986
[TBL] [Abstract][Full Text] [Related]
39. Role of micafungin in the antifungal armamentarium.
Ikeda F; Tanaka S; Ohki H; Matsumoto S; Maki K; Katashima M; Barrett D; Aoki Y
Curr Med Chem; 2007; 14(11):1263-75. PubMed ID: 17504145
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
